Literature DB >> 33739156

Soluble guanylate cyclase stimulation in late gestation does not mitigate asymmetric intrauterine growth restriction or cardiovascular risk induced by placental ischemia in the rat.

Laura E Coats1, Bhavisha A Bakrania1,2, Daniel R Bamrick-Fernandez1, Allison M Ariatti1, Adam Z Rawls1, Norma B Ojeda3, Barbara T Alexander1.   

Abstract

Stimulation of soluble guanylate cyclase (sGC) improves fetal growth at gestational day 20 in the reduced uterine perfusion pressure (RUPP) rat model of placental ischemia suggesting a role for sGC in the etiology of intrauterine growth restriction (IUGR). This study tested the hypothesis that stimulation of sGC until birth attenuates asymmetric IUGR mitigating increased cardiovascular risk in offspring. Sham or RUPP surgery was performed at gestational day 14 (G14); vehicle or the sGC stimulator Riociguat (10 mg/kg/day sc) was administered G14 until birth. Birth weight was reduced in offspring from RUPP [intrauterine growth restricted (IUGR)], sGC RUPP (sGC IUGR), and sGC Sham (sGC Control) compared with Sham (Control). Crown circumference was maintained, but abdominal circumference was reduced in IUGR and sGC IUGR compared with Control indicative of asymmetrical growth. Gestational length was prolonged in sGC RUPP, and survival at birth was reduced in sGC IUGR. Probability of survival to postnatal day 2 was also significantly reduced in IUGR and sGC IUGR versus Control and in sGC IUGR versus IUGR. At 4 mo of age, blood pressure was increased in male IUGR and sGC IUGR but not male sGC Control born with symmetrical IUGR. Global longitudinal strain was increased and stroke volume was decreased in male IUGR and sGC IUGR compared with Control. Thus late gestational stimulation of sGC does not mitigate asymmetric IUGR or increased cardiovascular risk in male sGC IUGR. Furthermore, late gestational stimulation of sGC is associated with symmetrical growth restriction in sGC Control implicating contraindications in normal pregnancy.NEW & NOTEWORTHY The importance of the soluble guanylate cyclase-cGMP pathway in a rat model of placental ischemia differs during critical windows of development, implicating other factors may be critical mediators of impaired fetal growth in the final stages of gestation. Moreover, increased blood pressure at 4 mo of age in male intrauterine growth restriction offspring is associated with impaired cardiac function including an increase in global longitudinal strain in conjunction with a decrease in stroke volume, ejection fraction, and cardiac output.

Entities:  

Keywords:  blood pressure; cardiac dysfunction; intrauterine growth restriction; placental ischemia; soluble guanylate cyclase

Mesh:

Substances:

Year:  2021        PMID: 33739156      PMCID: PMC8428889          DOI: 10.1152/ajpheart.00033.2021

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  75 in total

1.  Cardiovascular programming in children born small for gestational age and relationship with prenatal signs of severity.

Authors:  Fatima Crispi; Francesc Figueras; Monica Cruz-Lemini; Joaquim Bartrons; Bart Bijnens; Eduard Gratacos
Journal:  Am J Obstet Gynecol       Date:  2012-05-16       Impact factor: 8.661

2.  Persistence of Cardiac Remodeling in Preadolescents With Fetal Growth Restriction.

Authors:  Sebastian Imre Sarvari; Merida Rodriguez-Lopez; Marta Nuñez-Garcia; Marta Sitges; Alvaro Sepulveda-Martinez; Oscar Camara; Constantine Butakoff; Eduard Gratacos; Bart Bijnens; Fatima Crispi
Journal:  Circ Cardiovasc Imaging       Date:  2017-01       Impact factor: 7.792

3.  Development of an excitatory kisspeptin projection to the oxytocin system in late pregnancy.

Authors:  Alexander J Seymour; Victoria Scott; Rachael A Augustine; Gregory T Bouwer; Rebecca E Campbell; Colin H Brown
Journal:  J Physiol       Date:  2016-10-02       Impact factor: 5.182

4.  Plasma and 24-h NO(x) and cGMP during normal pregnancy and preeclampsia in women on a reduced NO(x) diet.

Authors:  K P Conrad; L J Kerchner; M D Mosher
Journal:  Am J Physiol       Date:  1999-07

5.  Fetal growth restriction results in remodeled and less efficient hearts in children.

Authors:  Fàtima Crispi; Bart Bijnens; Francesc Figueras; Joaquim Bartrons; Elisenda Eixarch; Ferdinand Le Noble; Asif Ahmed; Eduard Gratacós
Journal:  Circulation       Date:  2010-05-24       Impact factor: 29.690

6.  Effect of early-onset preeclampsia on cardiovascular risk in the fifth decade of life.

Authors:  Anouk Bokslag; Pim W Teunissen; Constantijn Franssen; Floortje van Kesteren; Otto Kamp; Wessel Ganzevoort; Walter J Paulus; Christianne J M de Groot
Journal:  Am J Obstet Gynecol       Date:  2017-02-14       Impact factor: 8.661

7.  Prenatal dexamethasone programs hypertension and renal injury in the rat.

Authors:  Luis A Ortiz; Albert Quan; Francisco Zarzar; Arthur Weinberg; Michel Baum
Journal:  Hypertension       Date:  2003-02       Impact factor: 10.190

8.  L-arginine attenuates hypertension in pregnant rats with reduced uterine perfusion pressure.

Authors:  Barbara T Alexander; Maria T Llinas; Walter C Kruckeberg; Joey P Granger
Journal:  Hypertension       Date:  2004-02-09       Impact factor: 10.190

9.  Pregnancy increases soluble and particulate guanylate cyclases and decreases the clearance receptor of natriuretic peptides in ovine uterine, but not systemic, arteries.

Authors:  H Itoh; I M Bird; K Nakao; R R Magness
Journal:  Endocrinology       Date:  1998-07       Impact factor: 4.736

10.  Poor spontaneous and oxytocin-stimulated contractility in human myometrium from postdates pregnancies.

Authors:  Sarah Arrowsmith; Siobhan Quenby; Andrew Weeks; Theodor Burdyga; Susan Wray
Journal:  PLoS One       Date:  2012-05-10       Impact factor: 3.240

View more
  1 in total

Review 1.  Placental Ischemia Says "NO" to Proper NOS-Mediated Control of Vascular Tone and Blood Pressure in Preeclampsia.

Authors:  Ana C Palei; Joey P Granger; Frank T Spradley
Journal:  Int J Mol Sci       Date:  2021-10-19       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.